Koyfin Home > Directory > Health Care > Agenus Inc

Agenus Inc Price Chart AGEN

Historical daily share price chart and data for Agenus Inc since 2000 adjusted for splits and dividends. The latest closing price for Agenus Inc as of October 29, 2020 is $3.72.
  • In 2020 the stock opened at $4.08 and closed at $3.72 for a loss of -10% YTD.
  • In 2019 the stock opened at $2.30 and closed at $4.07 for a gain of 43%.
  • In 2018 the stock opened at $3.29 and closed at $2.38 for a loss of -38%.
  • In 2017 the stock opened at $4.18 and closed at $3.26 for a loss of -28%.
View Chart On Koyfin

Agenus Inc Summary

Stock Symbol: AGEN

Agenus Inc Company Info

Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFβ TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Market Cap
Dividend Yield
0 %
Beta vs SPX
Short Interest
2338.16 %
30D Volatility
Hedge Fund Held
4.06 %

Last 10 Days of AGEN Prices